Saturday, April 2, 2011

Oncodesign offers world's most comprehensive collection of Colorectal tumor patient-derived models


Current article ratings:
Patients / public:not yet ratedhealthcare Prof:5 stars5 (1 votes)
Oncodesign today announced that the company exclusive rights acquired world's most comprehensive collection of human colorectal cancer models that distribute directly from tumors of the patient. Oncodesign of the client can now evaluate the entire collection in the Haus therapeutic compounds or carry out preclinical studies with Oncodesign access. This new collection has developed Oncodesign's Chi-Mice(R)-Plattform, to state-of-the-art integrated preclinical models of human samples. The Chi-Mice(R)-Plattform includes both reconstituted human immune system to NSG/NOG mice and models with patients derived tumors xenografted.

"This collection is the result of a five year research programme, and is the most comprehensive worldwide on the spectrum of genetic heterogeneity and characterization." It is a breakthrough in the evaluation of colorectal cancer therapies, "said Philippe Genne, President and CEO of Oncodesign." "The CReMEC collection ensures low passage experimental models to clinical reality adapted." This is more relevant, as required, which many years old, may be grown in tissue culture preclinical research generally on the cell lines, and then grafted on mice. "Cell lines can in different genetic profiles drifts and are not reliable enough, write a review to cancer therapies."

CReMEC brings together a highly qualified and complementary skills of world-class French Institute, three pharmaceutical companies and Oncodesign as project manager. The EUR 5.4 million program was developed to industrial requirements and strict guidelines were observed from conception to characterization. Plenty of characterization is available with every model. Clinical, molecular biology, pharmacological and histological data has been carefully compiled and gathered in a dedicated database, in parallel with a bio Bank of more than 5,000 samples. The CReMEC collection and derivatives represent a value base for Oncodesign of clients and academic institutions now implementation of research projects with these resources.

Based on this initial success, Oncodesign says that the Consortium is, considering the development of a special national platform. The challenge is, cancer patient offer derived models for all cancer pathology to unmet needs in cancer research.

Source:
Oncodesign biotechnology
Digg Google Bookmarks reddit Mixx StumbleUpon Technorati Yahoo! Buzz DesignFloat Delicious BlinkList Furl

0 comments: on "Oncodesign offers world's most comprehensive collection of Colorectal tumor patient-derived models"

Post a Comment